Kenvue Sales Rise 3.2% For A Fourth Straight Quarter, But No Guidance Or Call Ahead Of Kimberly-Clark Deal
The Tylenol maker's operating margin widened to 18.2% and nine-month free cash flow reached $1.6 billion.
Kenvue, the consumer health company behind Tylenol and Band-Aid, said third-quarter net sales rose 3.2% and operating margin widened, in results released Friday. Because of its pending transaction with Kimberly-Clark, it is giving no forward-looking guidance and holding no quarterly conference call.
Volume and pricing both contributed
Organic sales, which exclude currency swings and acquisitions or divestitures, rose 2.9%, with volume up 1.6% and pricing and mix up 1.3%. Currency added 0.3 percentage points. It was the fourth consecutive quarter of net and organic sales growth, the company said in an 8-K furnishing the results for the quarter ended September 27, 2026.
Self Care led, with organic sales up 5.4%. The company cited a rebound in Asia Pacific after last year's trade inventory depletion, a Motrin outperformance as flu cases rose, and low double-digit growth in smoking cessation led by Nicorette. In the U.S., Tylenol gained market share despite lower seasonal incidence and category softness.
Essential Health organic sales rose 2.5%, helped by Johnson's Baby, Stayfree, o.b. and Band-Aid wound care. Skin Health and Beauty organic sales fell 0.5%, with volume down 1.7%, on U.S. distribution losses, promotion timing and retailer negotiations in Europe. Hair Care grew at a low double-digit rate, led by Rogaine.
Margins widen, tax rate climbs
Operating margin reached 18.2%, from 16.7% a year earlier. Adjusted operating margin was 21.9%, against 21.5%. Gross margin was 59.5%, from 59.1%, helped by supply chain savings, U.S. tariff refunds and pricing.
Diluted earnings per share rose 5% to $0.22, and adjusted diluted earnings per share rose 4% to $0.29. The effective tax rate rose to 29.4% from 24.3%, mainly because fewer favorable one-time tax adjustments, partly offset by tax law changes.
For the first nine months, free cash flow rose to $1.6 billion from $1.0 billion, as operating cash flow reached $1.9 billion from $1.3 billion. Total debt was $8.2 billion at quarter end, versus $8.5 billion at December 28, 2025.
A deal that replaces the forecast
Kenvue sells consumer health products, including over-the-counter medicines, skin care and personal care under brands such as Tylenol, Neutrogena, Aveeno and Listerine, in more than 165 countries. Net sales were $15.1 billion in fiscal 2025, according to its annual report.
CEO Kirk Perry said the company is nearing completion of its "value-creating combination with Kimberly-Clark." Kenvue also cited savings from a 2026 restructuring initiative approved by the board on February 17, 2026, which is expected to carry about $250 million in pre-tax charges in fiscal 2026.
Kenvue said it will post the results release at investors.kenvue.com in place of a call.
Sources
- 8-K Filing — Kenvue Inc. (KVUE) — SEC EDGAR
- Exhibit q326earningspressrelease.htm — Kenvue Inc. 8-K exhibit — SEC EDGAR
- Kenvue Reports Third Quarter 2026 Results — businesswire.com